Advertisement
New Zealand markets close in 3 hours 37 minutes
  • NZX 50

    11,756.18
    -15.63 (-0.13%)
     
  • NZD/USD

    0.6122
    +0.0000 (+0.01%)
     
  • NZD/EUR

    0.5711
    -0.0003 (-0.05%)
     
  • ALL ORDS

    8,005.40
    -6.70 (-0.08%)
     
  • ASX 200

    7,764.20
    -5.20 (-0.07%)
     
  • OIL

    82.34
    +0.17 (+0.21%)
     
  • GOLD

    2,375.20
    +6.20 (+0.26%)
     
  • NASDAQ

    19,752.30
    -156.56 (-0.79%)
     
  • FTSE

    8,272.46
    +67.35 (+0.82%)
     
  • Dow Jones

    39,134.76
    +299.90 (+0.77%)
     
  • DAX

    18,254.18
    +186.27 (+1.03%)
     
  • Hang Seng

    18,335.32
    0.00 (0.00%)
     
  • NIKKEI 225

    38,691.81
    +58.79 (+0.15%)
     
  • NZD/JPY

    97.3270
    +0.1070 (+0.11%)
     

Which Is the Better Passive Income Stock, Eli Lilly or Bristol Myers Squibb?

Which Is the Better Passive Income Stock, Eli Lilly or Bristol Myers Squibb?

Most pharma investors are familiar with power players like Eli Lilly (NYSE: LLY) and Bristol Myers Squibb, (NYSE: BMY) and both businesses have a lot to offer passive income investors too. As one of the world's most preeminent pharma conglomerates, Eli Lilly and its portfolio of products covers all sorts of illnesses, including Alzheimer's disease, diabetes, and different cancers. It also has 21 programs in phase 3 clinical trials, and another 21 in phase 2 trials.